Literature DB >> 1693592

Variable expression of leucocyte-common (CD45) antigen in CD30 (Ki1)-positive anaplastic large-cell lymphoma: implications for the differential diagnosis between lymphoid and nonlymphoid malignancies.

B Falini1, S Pileri, H Stein, D Dieneman, F Dallenbach, G Delsol, O Minelli, S Poggi, M F Martelli, G Pallesen.   

Abstract

Monoclonal antibodies (mAbs) directed against the leucocyte common (CD45) antigen have been proposed as a useful tool for the differential diagnosis between malignant lymphomas (CD45+) and poorly differentiated nonhemopoietic tumors (CD45-). Thanks to the availability of mAbs directed against fixative-resistant epitopes of the CD45 molecule, this distinction can now easily be made even in routinely processed tissues. However, a small percentage of morphologically poorly defined neoplasms are difficult to diagnose even with the help of immunohistochemistry. The investigators report that 63 out of 165 anaplastic large-cell (ALC) lymphomas did not show any reactivity for the CD45 antigen in paraffin sections. In routine biopsies, the lymphomatous nature of these cases, most of which had been sent for consultation, could be always unequivocally established by demonstrating negativity for cytokeratins (mAb KL1) and clear dot-like and/or surface reactivity with the Ber-H2 mAb, which is directed against a fixative-resistant epitope of the lymphoid cell activation antigen CD30. Strikingly, 54% of the CD45-cases reacted with mAbs directed against fixative-resistant epitopes of the T cell-restricted CD45RO antigen (mAb UCHL1) or the B-restricted molecules CD45RA (mAb 4KB5) and L26 (unclustered). In order to avoid confusion of ALC lymphomas with anaplastic nonlymphoid tumors, pathologists must be aware of the existence of CD30+/CD45- ALC lymphomas, as they can mimic the above-mentioned malignancies both morphologically (due to the sinusoidal growth pattern) and phenotypically (due to the expression of EMA). The investigators conclude that the combined use of mAbs directed against fixative-resistant epitopes of the CD30, CD45RO, CD45RA, and L26 antigens and cytokeratins is essential for the correct diagnosis and treatment of these equivocal cases.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1693592     DOI: 10.1016/s0046-8177(96)90009-x

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  17 in total

Review 1.  The molecular biology of B-cell lymphoma: clinicopathologic implications.

Authors:  P M Kluin; J H van Krieken
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

2.  A case of primary gastric CD30-positive anaplastic large-cell lymphoma.

Authors:  Hun Ho Song; Gwang Ho Baik; Jung Hye Kwon; Keun Seok Lee; Young Hee Choi; Kyung Chan Choi; Young Eui Park
Journal:  J Korean Med Sci       Date:  2005-12       Impact factor: 2.153

3.  Common acute lymphoblastic leukaemia-lymphoma expressing cytokeratin: a case report.

Authors:  F Menestrina; M Lestani; A Scarpa; G Viale; F Bonetti; G Pizzolo; M Chilosi
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

4.  Childhood non-Hodgkin lymphomas in the United Kingdom: findings from the UK Children's Cancer Study Group.

Authors:  D Wright; P McKeever; R Carter
Journal:  J Clin Pathol       Date:  1997-02       Impact factor: 3.411

5.  Cytokeratin expression and vimentin content in large cell anaplastic lymphomas and other non-Hodgkin's lymphomas.

Authors:  C Gustmann; M Altmannsberger; M Osborn; H Griesser; A C Feller
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

Review 6.  Hodgkin's lymphoma: the pathologist's viewpoint.

Authors:  S A Pileri; S Ascani; L Leoncini; E Sabattini; P L Zinzani; P P Piccaluga; A Pileri; M Giunti; B Falini; G B Bolis; H Stein
Journal:  J Clin Pathol       Date:  2002-03       Impact factor: 3.411

7.  [Primary cutaneous CD30+ ALK(-) anaplastic large cell T-cell lymphoma].

Authors:  C Mühlhoff; A Rübben; N Gassler; M Megahed
Journal:  Hautarzt       Date:  2009-12       Impact factor: 0.751

8.  Relation of CD30 expression to survival and morphology in large cell B cell lymphomas.

Authors:  L A Noorduyn; P C de Bruin; P van Heerde; M M van de Sandt; G J Ossenkoppele; C J Meijer
Journal:  J Clin Pathol       Date:  1994-01       Impact factor: 3.411

9.  Anaplastic large cell lymphoma, CD30/Ki-1 positive, expressing the CD15/Leu-M1 antigen. Immunohistochemical and morphological relationships to Hodgkin's disease.

Authors:  R Rosso; M Paulli; U Magrini; S Kindl; E Boveri; G Volpato; S Poggi; P Baglioni; S Pileri
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

10.  Pathobiology of hodgkin lymphoma.

Authors:  Pier Paolo Piccaluga; Claudio Agostinelli; Anna Gazzola; Claudio Tripodo; Francesco Bacci; Elena Sabattini; Maria Teresa Sista; Claudia Mannu; Maria Rosaria Sapienza; Maura Rossi; Maria Antonella Laginestra; Carlo A Sagramoso-Sacchetti; Simona Righi; Stefano A Pileri
Journal:  Adv Hematol       Date:  2010-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.